# Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Published: 2026-09-23 · Updated: 2026-09-23 · Category: Funding

Source page: https://www.sipply.dev/story/enveda-secures-311m-to-bring-more-nature-derived-ai-drugs-7a1fccf9 · 中文: https://www.sipply.dev/zh/story/enveda-secures-311m-to-bring-more-nature-derived-ai-drugs-7a1fccf9

## Summary

Enveda, a biotech startup specializing in AI-driven drug discovery from natural sources, has successfully raised $311 million in a Series E funding round. This significant funding boost elevates the company's valuation to $2 billion and positions it to advance its pipeline of nature-derived drugs into clinical trials. Currently, Enveda is testing several drug candidates in patients, highlighting its commitment to integrating AI technology with biopharmaceutical innovation.

## Key takeaways

- Enveda has raised $311 million to enhance its drug discovery efforts.
- The funding will support the advancement of nature-derived drugs into clinical trials.
- Enveda's valuation has reached $2 billion, reflecting investor confidence in its AI-driven approach.

## Why it matters

This funding round underscores the growing interest in AI applications within the biotech sector, particularly for drug discovery from natural sources. It signals a shift towards leveraging technology to unlock the potential of nature in medicine.

- **Product managers:** For product managers, this development highlights the importance of understanding funding trends in biotech, which can influence product development timelines and market entry strategies.
- **Developers:** Developers and engineers should note the increasing integration of AI in drug discovery, presenting opportunities to work on innovative projects that combine technology with healthcare solutions.
- **Students and job seekers:** For students and job-seekers, this funding success indicates a growing field in biotech and AI, suggesting potential career opportunities in companies focused on innovative drug discovery methods.

## Sources

- [Enveda secures $311M to bring more nature-derived AI drugs into clinical trials](https://techcrunch.com/2026/09/23/enveda-secures-311m-to-bring-more-nature-derived-ai-drugs-into-clinical-trials) (TechCrunch AI, 2026-09-23)

## 中文

### Enveda获得3.11亿美元融资，将更多自然衍生的AI药物推向临床试验

Enveda是一家专注于从自然来源进行AI驱动药物发现的生物技术初创公司，成功在E轮融资中筹集了3.11亿美元。这一重要的资金提升使公司的估值达到20亿美元，并为其将自然衍生药物推进临床试验奠定了基础。目前，Enveda正在对多个药物候选者进行患者测试，突显其将AI技术与生物制药创新相结合的承诺。

**要点：**

- Enveda筹集了3.11亿美元以增强其药物发现工作。
- 这笔资金将支持自然衍生药物的临床试验进展。
- Enveda的估值已达到20亿美元，反映出投资者对其AI驱动方法的信心。

**为什么重要：** 这一轮融资凸显了生物技术领域对AI应用的日益关注，特别是在从自然来源进行药物发现方面。这标志着利用技术释放自然在医学中潜力的转变。

---
Sipply: Sip AI News Simply. https://www.sipply.dev